LeMaitre Vascular Q1 Sales Rise 11%, EPS Up 42%, Raises 2026 Guidance
LeMaitre Vascular posted Q1 2026 sales of $66.6 million, up 11% (10% organic), operating income climbed 41% to $17.8 million and EPS jumped 42% to $0.68. The board declared a $0.25/share dividend, authorized a $100 million buyback and raised full-year 2026 sales guidance to $280 million with EPS of $3.00.
1. Q1 2026 Results
LeMaitre Vascular reported Q1 revenue of $66.6 million, an 11% increase year-over-year (10% organic). Gross margin expanded 350 basis points to 72.7%, operating income rose 41% to $17.8 million and EPS increased 42% to $0.68, with cash balances up $8.1 million to $367.2 million.
2. Product and Regional Growth
Sales of Artegraft devices grew 36% globally following its international launch, while grafts, valvulotomes and carotid shunts set quarterly records with 20%, 15% and 11% growth respectively. All regions hit record revenue—EMEA up 20%, APAC up 18% and the Americas up 7%.
3. Capital Return Initiatives
The board declared a quarterly dividend of $0.25 per share payable June 4 to holders of record May 21. It also authorized repurchase of up to $100 million of common stock under a program running through February 18, 2027.
4. 2026 Outlook
For Q2, management forecasts sales of $70.5–72.5 million (11% growth), a 30% operating margin and EPS of $0.79–0.84. Full-year guidance calls for $277–283 million in sales (12% growth), a 29% operating margin and EPS of $2.93–3.08 (midpoint implying 24% adjusted EPS growth).